(Q24234794)

English

Daclizumab for relapsing remitting multiple sclerosis

scientific article (publication date: 16 June 2010)

In more languages

edit

Statements

0 references

1 reference

Europe PubMed Central

title

Daclizumab for relapsing remitting multiple sclerosis (English)

0 references

main subject

relapsing-remitting multiple sclerosis

0 references

multiple sclerosis

0 references

author name string

Jia Liu

series ordinal

1

0 references

Luning Wang

series ordinal

2

0 references

Siyan Zhan

series ordinal

3

0 references

Jiping Tan

series ordinal

4

0 references

Yinyin Xia

series ordinal

5

0 references

publication date

16 June 2010

0 references

published in

Cochrane Database of Systematic Reviews

0 references

cites work

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB2

retrieved

21 January 2018

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB2

retrieved

21 January 2018

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB2

retrieved

21 January 2018

Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB2

retrieved

21 January 2018

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB2

retrieved

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB2

retrieved

21 January 2018

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB2

retrieved

21 January 2018

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB2

retrieved

21 January 2018

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB2

retrieved

21 January 2018

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB2

retrieved

21 January 2018

Daclizumab in treatment of multiple sclerosis patients

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB2

retrieved

21 January 2018

Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD008127.PUB2

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD008127.PUB2

0 references

PubMed publication ID

20556791

0 references

(Q24234794)

Daclizumab for relapsing remitting multiple sclerosis

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)